AzTrials
AzTrials

Urinary Stress IncontinenceNCT03881293

Effects of Topical Lidocaine During Urodynamic Testing In Women

A study testing lidocaine 2% gel and water soluble lubricant in people with Urinary Stress Incontinence and Pain, run by Kristine Zinkgraf.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Urodynamic testing is used to help diagnose causes of urinary incontinence and voiding dysfunction. The purpose of the urodynamic test is to gain insight into the patient's urinary symptoms and assist in making a diagnosis. Catheter insertion and manipulation during the test can be uncomfortable for the patient. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Urinary Stress Incontinence, Pain
What is being tested?
lidocaine 2% gel and water soluble lubricant
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
110 participants
Where
No sites listed yet
Study dates
Dec 2013to Dec 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Women with complaint of stress urinary incontinence who were scheduled for a urodynamic test Patients with symptomatic pelvic organ prolapse if they also had stress incontinence symptoms.
  • Community dwelling elderly patients who were able to provide their own history and were able to sign for themselves

Who cannot join

  • Patients who were unable to provide their own consent Patients who are allergic to lidocaine Children and pregnant patients

About this study

Urodynamic testing is used to help diagnose causes of urinary incontinence and voiding dysfunction. The purpose of the urodynamic test is to gain insight into the patient's urinary symptoms and assist in making a diagnosis. Catheter insertion and manipulation during the test can be uncomfortable for the patient. Lidocaine gel has not been used routinely during urodynamic testing. However, it is used routinely during outpatient cystoscopy and with any urethral catheterization. The investigators proposed that lidocaine numbing gel could be used without compromising test findings.

The study included 110 adult women. The purpose was:

  1. Determine whether the use of topical lidocaine during urodynamic testing decreases patient discomfort during the procedure.
  2. Evaluate whether the use of topical lidocaine affects the urodynamic results.
Read the detailed description

Topical Lidocaine For Urodynamic Testing: A Double Blinded Randomized Control Trial

Hypothesis / aims of study

  1. Determine whether the use of topical lidocaine during urodynamic testing decreases patient discomfort during the procedure.
  2. Evaluate whether the use of topical lidocaine affects the urodynamic results.

Study design, materials and methods The hospital IRB approved the study. Women with symptoms of stress urinary incontinence (SUI) scheduled for a urodynamic study (UDS) were eligible to participate. Women presenting with predominant overactive bladder symptoms were excluded. Participants were randomized on the day of the procedure using Random Allocation Software Version 1.0. All were blinded to the study arms until completion of final data analysis. Participant randomization assignment was known only to an independent research nurse and the dispensing pharmacist. The study consisted of transurethral administration of 5 ml lidocaine 2% gel or surgilube gel, in the study and control arms, respectively, 10 minutes before catheter insertion. Prior to testing, a 24 hour bladder diary and the Pelvic Floor Distress Inventory - Short Form 20 were completed. During the UDS participants were asked for sensory information including desire to void and maximal cystometric capacity (MCC). Urethral pressure profiles were obtained at an infused volume of 200 ml. Provocative measures were performed to assess SUI. Using a Likert scale, pain was assessed prior to and after catheter insertion, after performing the urethral pressure profile, and at the completion of the study. The primary outcome; pain after urethral pressure profile (UPP), was compared between the two groups. Comparisons of the bladder diary and UDS results were made between study and control arms individually and in-between groups.

Statistical methods The effect of lidocaine on patient pain as reported during multiple time-points during the UDS was evaluated using repeated measures analysis via mixed effects regression with a random patient-specific intercept. This approach allows the evaluation of the overall pain experience, as well as baseline-adjusted comparison at individual time-points. Comparisons were done using t-tests for continuous variables, Chi-squared test for categorical variables, Wilcoxon rank-sum test, Lin's Concordance Correlation Coefficient (CCC), and a z-test. The CCC provides a generalization of Pearson's correlation coefficient that measures how well the data align with the diagonal representing equal values for the two measurements (as opposed to any straight line). Agreement is stronger than correlation. Specifically, the agreement between mean void volume and volume at strong desire, as well as between maximum void volume and volume at MCC were computed separately for each study group. The CCC values were compared between the study groups using a z-test. Power calculations determined a total sample size of 110 participants was needed to detect significant differences between the groups with at least 94% statistical power.

Being tested
lidocaine 2% gel, water soluble lubricant
Keywords
urodynamics, women, lidocaine gel
Medical subject headings
Urinary Incontinence, Stress, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • lidocaine 2% gelDrug

    Transurethral instillation of 5 ml lidocaine 2% gel

  • water soluble lubricantDrug

    Transurethral instillation of 5 ml water soluble lubricant

Study groups in NCT03881293
Study groupRoleWhat they receive
Placebo Lubricant GelPlacebo comparator5 ml water-soluble gel instilled transurethrally ten minutes prior to catheter insertion
Receives: Drug: water soluble lubricant
Lidocaine 2% GelActive comparator5 ml lidocaine 2% gel instilled transurethrally ten minutes prior to catheter insertion
Receives: Drug: lidocaine 2% gel

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in pain immediately after urethral pressure profilometry

    Patient rated pain using Likert Scale of 0-10 (0 is no pain and 10 is worst pain)

    Measured: Pain was assessed immediately after urethral pressure profilometry was performed

Secondary outcomes (2)
  1. Demonstration of stress urinary incontinence during the urodynamic test

    Ability to demonstrate stress urinary incontinence during the urodynamic test

    Measured: During the urodynamic test

  2. Perception of bladder filling

    Correlation of maximal cystometric capacity on urodynamic test and maximal voided volume on bladder diary

    Measured: During the urodynamic test

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Mar 2019
  2. Study startDec 2013
  3. Primary completionDec 2016
  4. Study completionDec 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
Double Blinded Randomized Control Trial
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
110 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03881293
Sponsor's protocol ID
IRB#12-09
Status last verified
Mar 2019
First submitted
15 Feb 2019
Last updated
19 Mar 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing lidocaine 2% gel and water soluble lubricant in people with Urinary Stress Incontinence and Pain, run by Kristine Zinkgraf.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in pain immediately after urethral pressure profilometry (time frame: Pain was assessed immediately after urethral pressure profilometry was performed). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in